T A Lane1, A D Ho, A Bashey, S Peterson, D Young, P Law. 1. Blood and Marrow Transplant Program, Department of Medicine, University of California, San Diego, School of Medicine, USA.
Abstract
BACKGROUND: It was previously reported that the combination of granulocyte-macrophage-colony-stimulating factor (GM-CSF) and granulocyte-CSF (G-CSF) for 4 days mobilized more primitive CD34+ subsets than did either G-CSF or GM-CSF alone. STUDY DESIGN AND METHODS: The studies determine the optimal number of days of growth factor dosing for mobilization and collection of peripheral blood progenitor cells, by increasing the days of administration of GM-CSF and/or G-CSF or employing the sequential administration of GM-CSF followed by G-CSF. Sixty normal subjects were given injections of G-CSF or GM-CSF alone; GM-CSF and G-CSF concurrently for 4, 5, or 6 days; or a sequential regimen of GM-CSF for 3 or 4 days followed by G-CSF for 2 or 3 days. A 10-L apheresis was performed 24 hours after the last dose. RESULTS: The three most efficacious mobilization regimens consisted of sequential GM-CSF for 3 days followed by G-CSF for either 2 or 3 days and G-CSF alone for 5 days. Each of these regimens resulted in the collection of significantly greater numbers of CD34+ cells by apheresis than any of the 4-day dosing regimens with G-CSF and/or GM-CSF (sequential GM-CSF/G-CSF: 3 days/2 days = 3.58 +/- 0.53 x 106 CD34+ cells/kg; GM-CSF/G-CSF: 3 days/3 days = 4.45 +/- 1.08 x 10(6) CD34+ cells/kg; G-CSF: 5 days = 3.58 +/- 0.97 x 10(6) CD34+ cells/kg; all p<0.05 vs. G-CSF and/or GM-CSF for 4 days). Clonogenic assays generally paralleled the level of CD34+ cells. Regimens containing GM-CSF resulted in a higher percentage of the cells from primitive CD34+/CD38-/HLA-DR+ subset than G-CSF alone. CONCLUSION: Compared with 4-day dosing regimens with G-CSF and/or GM-CSF, mobilization of CD34+ cells in normal subjects using sequential GM-CSF for 3 days followed by G-CSF for 2 or 3 days or using G-CSF alone for 5 days increased the number CD34+ cells that can be collected by a single 10-L apheresis 24 hours after the last dose of cytokine.
BACKGROUND: It was previously reported that the combination of granulocyte-macrophage-colony-stimulating factor (GM-CSF) and granulocyte-CSF (G-CSF) for 4 days mobilized more primitive CD34+ subsets than did either G-CSF or GM-CSF alone. STUDY DESIGN AND METHODS: The studies determine the optimal number of days of growth factor dosing for mobilization and collection of peripheral blood progenitor cells, by increasing the days of administration of GM-CSF and/or G-CSF or employing the sequential administration of GM-CSF followed by G-CSF. Sixty normal subjects were given injections of G-CSF or GM-CSF alone; GM-CSF and G-CSF concurrently for 4, 5, or 6 days; or a sequential regimen of GM-CSF for 3 or 4 days followed by G-CSF for 2 or 3 days. A 10-L apheresis was performed 24 hours after the last dose. RESULTS: The three most efficacious mobilization regimens consisted of sequential GM-CSF for 3 days followed by G-CSF for either 2 or 3 days and G-CSF alone for 5 days. Each of these regimens resulted in the collection of significantly greater numbers of CD34+ cells by apheresis than any of the 4-day dosing regimens with G-CSF and/or GM-CSF (sequential GM-CSF/G-CSF: 3 days/2 days = 3.58 +/- 0.53 x 106 CD34+ cells/kg; GM-CSF/G-CSF: 3 days/3 days = 4.45 +/- 1.08 x 10(6) CD34+ cells/kg; G-CSF: 5 days = 3.58 +/- 0.97 x 10(6) CD34+ cells/kg; all p<0.05 vs. G-CSF and/or GM-CSF for 4 days). Clonogenic assays generally paralleled the level of CD34+ cells. Regimens containing GM-CSF resulted in a higher percentage of the cells from primitive CD34+/CD38-/HLA-DR+ subset than G-CSF alone. CONCLUSION: Compared with 4-day dosing regimens with G-CSF and/or GM-CSF, mobilization of CD34+ cells in normal subjects using sequential GM-CSF for 3 days followed by G-CSF for 2 or 3 days or using G-CSF alone for 5 days increased the number CD34+ cells that can be collected by a single 10-L apheresis 24 hours after the last dose of cytokine.
Authors: Anurag Mehta; Kreton Mavromatis; Yi-An Ko; Steven C Rogers; Devinder S Dhindsa; Cydney Goodwin; Risha Patel; Mohammad A Martini; Mahadev Prasad; Ali Mokhtari; Iraj G Hesaroieh; Stephen C Frohwein; Michael H Kutner; Arash Harzand; Bryan J Wells; Yazan Duwayri; Olamide Alabi; Ravi R Rajani; Luke P Brewster; Edmund K Waller; Arshed A Quyyumi Journal: Contemp Clin Trials Date: 2020-03-04 Impact factor: 2.226
Authors: A Le Maux; G Noël; B Birebent; J-M Grosset; N Vu; S De Guibert; M Bernard; G Semana; L Amiot Journal: Clin Exp Immunol Date: 2008-01-28 Impact factor: 4.330
Authors: Simranpreet Kaur; Anuj Sehgal; Andy C Wu; Susan M Millard; Lena Batoon; Cheyenne J Sandrock; Michelle Ferrari-Cestari; Jean-Pierre Levesque; David A Hume; Liza J Raggatt; Allison R Pettit Journal: J Hematol Oncol Date: 2021-01-06 Impact factor: 17.388
Authors: Joseph Poole; Kreton Mavromatis; José N Binongo; Ali Khan; Qunna Li; Mohamed Khayata; Elizabeth Rocco; Matthew Topel; Xin Zhang; Charlene Brown; Matthew A Corriere; Jonathan Murrow; Salman Sher; Stephanie Clement; Khuram Ashraf; Amr Rashed; Tarek Kabbany; Robert Neuman; Alanna Morris; Arshad Ali; Salim Hayek; John Oshinski; Young-sup Yoon; Edmund K Waller; Arshed A Quyyumi Journal: JAMA Date: 2013-12-25 Impact factor: 157.335